Brought to you by 
ImmunoMolecular Therapeutics closes $10mm Series A round
21 May 2020
Executive Summary
ImmunoMolecular Therapeutics Inc. (personalized therapies for autoimmune diseases) raised $10mm in its Series A financing co-led by the JDRF T1D Fund and Morningside Ventures, which were joined by the Colorado University Healthcare Innovation Fund. According to the Form D, seven investors participated.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ImmunoMolecular Therapeutics closes $10mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice